लोड हो रहा है...

Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

BACKGROUND: Fibromyalgia patients from a long-term, open-label study of milnacipran (50–200 mg/day) were eligible to participate in a 12-week, randomized, placebo-controlled withdrawal study. The withdrawal study evaluated loss of therapeutic response in patients who achieved ≥50% pain improvements...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Pain Res
मुख्य लेखकों: Mease, Philip J, Clauw, Daniel J, Trugman, Joel M, Palmer, Robert H, Wang, Yong
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove Medical Press 2014
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247140/
https://ncbi.nlm.nih.gov/pubmed/25473309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JPR.S70200
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!